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Patients from higher rank hospitals received more TCHM treatment (OR=1.12, 
P<0.01) than their counter parts. Use of TCHM is also higher (OR=2.49, P<0.01) in 
eastern(developed area) than in mid-western(developing area). CONCLUSIONS: 
 F Factors associate with utilization of TCHM include both patient demand and 
TCHM service supply. The study calls for further investigations on availability of 
TCHM and practitioners in different geographic locations. It is also worthwhile to 
identify comparative advantages of TCHM to western medicine in treating 
different conditions in order to fulfill its roles with the current Chinese health 
care reform.  
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OBJECTIVES: China’s evolving health care market demands advanced oncology 
agents for its patients; however, the formulary (drug list) access system for these 
drugs is complex to navigate. This research aims to identify those critical factors 
that support formulary access and utilization for “advanced oncology agents 
(AOA)” in China. METHODS: Telephonic interviews were conducted with twelve 
formulary decision makers and influencers (FDM) from three large provinces in 
China, Beijing, Shanghai, and Guangzhou. FDM were identified and selected for 
their role in access and reimbursement decisions in their local health care 
systems, and included pharmacoeconomists, insurance officers, directors of 
hospital pharmacy, and key opinion leading oncologists (KOL). Each FDM was 
interviewed in their native language for 60 to 90 minutes. Responses were 
tabulated and analyzed. RESULTS: Interviews revealed that none of the AOA are 
covered in the National Reimbursement Drug List (NRDL), however, some are 
reimbursed at the provincial level on the Provincial Reimbursement Drug List 
(PRDL). The provinces that include AOA on their PRDL share common attributes, 
most notably, the local government has significant decision-making power, and 
its medical insurance fund has a relatively high balance. Factors that influence 
AOA utilization in China include physician willingness to prescribe, support by 
regional KOL, patient affordability, listing on hospital and provincial drug lists, 
and hospital budget. There are locally-funded insurance programs, and 
manufacturer-funded patient-assistance programs, available to help reduce the 
patient-burden of treatment for chronic and high-cost diseases. KOL are critical 
to the decisions to include AOA in these programs. CONCLUSIONS: The critical 
success factors that support access and utilization of AOA in China include 
advocacy for drug listing by regional KOL, achieving listing on local hospital drug 
lists, and inclusion of drugs in local insurance- and manufacturer-funded patient 
programs.  
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OBJECTIVES: Melanoma is a skin cancer originated in melanocytes and is 
predominant in white adults. Skin cancer is the most common cancer in Brazil 
corresponding to 25% of all malignant tumors registered. Melanoma accounts for 
only 4% of the malignant neoplasms of the skin, but it has very high lethality. 
The objective of this research is to describe resource utilization and costs 
associated with melanoma treatment in Brazil and across the country’s regions; 
to compare chemotherapy and surgery in relation to patients’ characteristics and 
average costs. METHODS: A sample of 3 million Brazilian supplementary health 
care system patients was accessed in a electronic administrative database 
(BI.2iM) to identify resource utilization in 2011. The search was retrospective and 
conducted using the melanoma ICD 10 code (C43) as driver. Cost information is 
in Brazilian reais (US$1.00 = R$ 2.00) RESULTS: 94 patients were identified by the 
melanoma IC10 code in 2011. These patients sample consumed R$ 9,1 million 
(mean annual cost of R$ 96,268) with 81% of these costs referred to surgical 
procedures, radiotherapy 12%, chemotherapy 1% and others expendures 6%. 
Projecting the number of cases found in BI.2iM in the population covered by 
health plans in Brazil it would be expected around 1,504 cases to be treated per 
year at a potential cost of 144, 7 million. CONCLUSIONS: This data suggest that 
surgical procedures are the main cost related with the melanoma treatment in 
the Brazilian supplementary health care system. Understanding treatment 
preferences and patterns is mandatory to analyze new treatments cost-
effectiveness ratio.  
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OBJECTIVES: With the approval of imatinib (ima), systemic therapy (ST) for 
gastrointestinal stromal tumors (GIST) has changed substantially. This study 
evaluated treatment patterns and costs of patients receiving first-line (1LT) ima 
for GIST. METHODS: A retrospective study spanning 1/1/03-9/30/11 was 
conducted utilizing pharmacy/medical claims data from a large health plan. 
Patients with GIST-related ICD9 codes who initiated ima were eligible. Patients 
were excluded if they received any chemotherapy prior to date of first diagnosis 
or ima. Adjuvant patients (APs) were defined as receiving GIST-related surgery 
prior to ima. Patients were followed from diagnosis to end of the study period or 
loss of continuous eligibility to describe post-ima ST and evaluate corresponding 
GIST-related average monthly costs. RESULTS: One hundred patients (45 APs) 
with average follow-up time of 1113 days (range 385–2,901 days) met all inclusion 
criteria. The average time between first diagnosis and initiation of ima therapy 
was 207 days for AP versus 140 days for non-adjuvant patients (NAPs). Average 
monthly costs prior to ima therapy were $7,025; APs, $11,095/month. APs 
remained on ima therapy for an average of 463 days versus 404 days for NAPs. 
Monthly therapy costs across both cohorts were $3919 (SD=$1822), almost 92% of 
total monthly costs. Twenty-one patients moved onto post-ima second-line 
therapy (2LT), with 81% (n=17) receiving sunitinib (sun). APs moving onto 
second-line therapy remained on treatment 148 days versus 256 days for NAPs. 
2LT average monthly cost: AP=$8813; NAP=$5894; over 70% related to ST. 6 of the 
21 patients received third-line therapy (3LT) (3-nilotinib, 2-sorafenib, 1-
cyclophosphamide) for an average of 48 days; treatment costs averaged 
$1774/month. CONCLUSIONS: Post-ima 2LT for GIST was dominated by sun, 
while 3LT varied among the few patients who initiated this line of care. Across 
all lines of care, therapy cost was the primary driver of cost.  
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OBJECTIVES: To investigate the effect of Medicare’s cut in chemotherapy 
reimbursement (implemented in 2004-2005) on rituximab prescription among 
Non-Hodgkin’s Lymphoma (NHL) patients and to estimate the marginal survival 
benefits of rituximab using an instrumental variable (IV) approach. METHODS: 
Using the Surveillance, Epidemiology and End Results (SEER)-Medicare linked 
database, we studied patients 66 years or older diagnosed with first primary NHL 
from 2002-2007 (N=19,424). Logistic regression was used to assess the impact of 
Medicare reimbursement cut on first course rituximab prescription, after 
controlling for clinical and non-clinical factors. Two stage least square 
regressions using Medicare reimbursement policy as IV were used to estimate 
whether the changes in the rituximab prescription rates could lead to one and 
three years of survival benefit. RESULTS: In the post-policy period (2004-2008) 
the likelihood of rituximab prescriptions increased as compared to the pre-policy 
period (AOR of 1.52 in 2004, AOR of 1.79 in 2005 and after, respectively). Using IV 
approach, we found that the first course of rituximab prescription among NHL 
patients significantly improved one- and three-year survival (effectiveness 
estimate=0.37 for one-year survival, effectiveness estimate=0.44 for three-year 
survival respectively). CONCLUSIONS: Rituximab prescriptions increased in 
response to the Medicare’s reimbursement cut. Substantial rituximab survival 
benefits were observed among marginal NHL patients whose treatment choices 
were affected by the policy change.  
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OBJECTIVES: The Medicare Prescription Drug, Improvement and Modernization 
Act of 2003 (MMA) changed reimbursement of outpatient drugs reimbursed 
under Medicare Part B from 95% of average wholesale price to 106% of the 
average sales price as a cost saving measure. Shortly thereafter many 
commercial payers followed suit. This analysis examines the impact of the 
change in the reimbursement schedules on actual payments provided to 
physicians for administrations of 5 high cost Part B reimbursed oncology drugs. 
METHODS: Using the MarketScan Research Databases©, claims for 
administrations of pemetrexed, bevacizumab, trastuzumab, rituximab, 
docetaxel, and zoledronic acid were identified from January 1, 2004 through 
December 31, 2011 among cancer patients with non-capitated commercial or 
employer-sponsored supplemental Medicare insurance. Claims were excluded 
from the payment analysis if the reimbursed amount was less than $100 to omit 
use for other indications, such as the use of bevacizumab for treatment of 
macular degeneration. Median reimbursed amounts, encompassing both plan 
and patient paid amounts, were reported by year, after adjusting to 2011 dollars 
using the consumer price index. Compound annual growth rates (CAGRs) 
between 2004 and 2011 were computed to assess the change in reimbursements 
over time. RESULTS: A total of 1.98M Commercial and 839k Medicare claims were 
analyzed. Negative CAGRs between 2004-2011 were observed in only two of the 
therapies: pemetrexed (-11% CAGR in Commercial population) and zoledronic 
acid (-2 % to -3% in the Medicare and Commercial population, respectively). The 
remaining oncology Part B therapies exhibited CAGRs of 1-5%, with the exception 
of trastuzumab which had 11-13% growth. CONCLUSIONS: The amount 
reimbursed for several key oncology therapies administered in providers offices 
did not shift dramatically downward after the implementation of MMA. Further 
research will examine shifts in dosage levels, frequency, and location of 
administrations (office vs. hospital) to determine the drivers of the upward shift 
in average reimbursed amount per claim.  
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